Not finding it? Sign in to also search OpenAlex live.
-
Longer-term safety of pimicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of phase 1 and phase 3 MANEUVER trial data.2026 Journal of Clinical Oncology conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments
Hans A. J. Gelderblom, Vinod Ravi, Vishal Ghori, Aimar Zhang, Niki Karachaliou, Boyao Shan, +2 more
0citations -
Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
Steffen Koschmieder, Susanne Isfort, Lino Lars Teichmann, Philippe Schafhausen, Florian Heinrich Heidel, Andreas Hochhaus, +18 more
4citations -
Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
Susanne Isfort, Kirsi Marjaana Manz, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +18 more
0citations -
Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study2021 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Raymond L. Comenzo, Giovanni O. Palladini, Efstathios Kastritis, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, +24 more
12citations -
The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial
Régis Peffault de Latour, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yutaka Ueda, Carlos de Castro, Samopriyo Maitra, +3 more
1citations -
Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
Andrew Jay Portuguese, Sherilyn Alvaran Tuazon, Margot J. Pont, Gabriel O. Cole, Blythe Duke Sather, Xiaoling Song, +17 more
0citations -
Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Jean‐Jacques Kiladjian, Alberto Álvarez‐Larrán, Konstanze Döhner
2citations -
Adding eltrombopag to immunosuppressive treatment with cyclosporine as front-line therapy for moderate aplastic anemia improves trilineage hematologic response: One-year analysis of the randomised, placebo-controlled, double-blind Phase III trial eltrombopag for moderate aplastic anemia (EMAA Trial)2025 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Blood disorders and treatments Open access
Britta Hoechsmann, Philippe Schafhausen, Fabian Beier, Michael Heuser, Joerg Westermann, Beatrice Drexler, +10 more
0citations -
P319 Characteristics of filgotinib-treated patients with Ulcerative Colitis who achieve sustained corticosteroid-free remission: Post hoc analysis of the phase 2b/3 SELECTION study2023 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Teruaki Kobayashi, AU Dignass, Xavier Roblin, Y Fujitani, Alessandra Faria Oortwijn, C Jamoul, +1 more
0citations -
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Hartmut Goldschmidt, Uta Bertsch, Ema Požek, Axel Benner, Roland R. Fenk, Britta Besemer, +26 more
1citations -
LY13 A confirmatory phase III multicentre, randomized, double-blind, placebo-controlled study of the efficacy of topical HyBryte™ (hypericin sodium) and visible-light activation for the treatment of cutaneous T-cell lymphoma: interim analysis results of primary efficacy and safety for FLASH22026 British Journal of Dermatology conference-abstract Medicine Cutaneous lymphoproliferative disorders research
Julia Jane Scarisbrick, Maarten H. Vermeer, Martine Bagot, Pablo Ortiz‐Romero, Pietro Quaglino, Ellen J. Kim, +1 more
0citations -
First safety analysis of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluoruracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC).2025 Journal of Clinical Oncology conference-abstract Medicine Pancreatic and Hepatic Oncology Research Open access
Dirk Waldschmidt, Nam Gyu Im, Alexander Ioannis Damanakis, Thomas Schmidt, Albrecht Meyer zu Schwabedissen, Alexander Quaas, +13 more
0citations -
POS0893 EFFICACY OF SECUKINUMAB ACROSS THE AXIAL SPONDYLOARTHRITIS SPECTRUM AMONG PATIENTS GROUPED BY AGE (≥40 YEARS VS <40): A POST HOC ANALYSIS OF 6 PHASE 3 TRIALS2025 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
Sofía Ramiro, Corine Gaillez, Uta Kiltz, Lianne S. Gensler, Chaitali Babanrao Pisal, J. Braun, +1 more
0citations -
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
Sonja Zweegman, Thierry T.F. Facon, Vânia Hungria, Nizar Jacques Bahlis, Christopher Paul Venner, Marc Justin Braunstein, +22 more
13citations -
DOP37 Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies2022 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Stefan Schreiber, Edward V. Loftus, Christian Maaser, Silvio Danese, C Rudolph, Rob Jongen, +2 more
5citations -
Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study2020 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Kenshi Suzuki, Ashutosh D. Wechalekar, Kihyun Kım, Chihiro Shimazaki, Jin Seok Kim, Takayuki Ikezoe, +15 more
2citations -
Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dl on anti-C5 therapy: Subgroup analysis of the appulse-pnh Phase 3b trial2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Austin Gladston Kulasekararaj, Flore Sicre de Fontbrune, Anna Gayà, Ilene Ceil Weitz, David J. Kuter, David J. Araten, +15 more
0citations -
MM-329 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)2024 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Multiple Myeloma Research and Treatments
Meletios Athanasios Dimopoulos, Pieter Sonneveld, Paula Rodríguez‐Otero, Hang Quach, P. Joy Ho, Meral Beksaç, +33 more
3citations -
THU0204 A SUBGROUP ANALYSIS OF LOW DISEASE ACTIVITY AND REMISSION FROM PHASE 3 STUDY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARDS2020 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access
J.E. Gottenberg, MH Buch, Roberto Felice Caporali, Grace C. Wright, Tsutomu Takeuchi, KENNETH C. KALUNIAN, +6 more
2citations -
MPN-161: Benefit of Rusfertide Maintained in Patients With Low-Risk or High-Risk Polycythemia Vera: Efficacy and Safety Subgroup Analysis From the Randomized Controlled Phase 3 VERIFY Study2026 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment
Naveen Pemmaraju, Valentín García‐Gutiérrez, Aniket Bankar, Kristen Marie Pettit, Joseph Shatzel, Alessandro Lucchesi, +19 more
0citations -
PL04.04 Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC2024 Journal of Thoracic Oncology conference-abstract Medicine Lung Cancer Treatments and Mutations Open access
Gerrina Ruiter, M-J. Ahn, Kiyotaka Yoh, Jon Zugazagoitia, Yi-Long Lung Cancer Wu, D. Planchard, +8 more
8citations -
MPN-274 Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analysis From the Phase 2 PATHFINDER Study With 3-Year Follow-up2024 Clinical Lymphoma Myeloma & Leukemia conference-abstract Immunology and Microbiology Mast cells and histamine
Andreas Reiter, Jason R. Gotlib, Deepti H. Radia, Iván Álvarez‐Twöse, Michael W. Deininger, Tracy I. George, +27 more
4citations -
OP0147 THE SLE-DAS REMISSION AND LOW DISEASE ACTIVITY STATES DISCRIMINATE DRUG FROM PLACEBO AND BETTER HEALTH-RELATED QUALITY OF LIFE: POST-HOC ANALYSIS OF THE BLISS-52 AND BLISS-76 PHASE III TRIALS.2citations